Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Familial Cancer
Published in: Familial Cancer 3/2011

Open Access 01-09-2011

Cancer worry among Norwegian male BRCA1/2 mutation carriers

Authors: Nina Strømsvik, Målfrid Råheim, Eva Gjengedal

Published in: Familial Cancer | Issue 3/2011

Login to get access

Abstract

This qualitative study explored the experiences of Norwegian men after being identified as BRCA 1/2 mutation-positive. Only limited knowledge is available on this topic; therefore, the aim of this study was to gain a deeper insight from the men’s own perspectives. Data were collected from in-depth interviews with 15 men and seven of their partners. The participants described fear of cancer development, and two main narrative patterns were identified: fear for their own health, including fear of developing cancer, and negative feelings about responsibility for others’ health. The men expressed fear of developing cancer themselves and described a need for genetic risk information. They were also deeply concerned about how the mutation might affect their children and other relatives. There is a need for guidelines concerning genetic risk information and follow-up programs for male BRCA 1/2 mutation carriers. This study adds valuable contextual insights into their experiences of living with fear of cancer.
Literature
1.
Levy-Lahad E, Friedman E (2007) Cancer risks among BRCA1 and BRCA2 mutation carriers. Br J Cancer 96(1):11–15PubMedCrossRef
2.
Møller P (2006) Diagnostikk og behandling av arvelig bryst-og eggstokkreft. Konsensusforslag NGAK, NBCG, NFGO verdr Tiltak ved arvelig bryst-og eggstokkreft
3.
Lux MP, Fasching PA, Beckmann MW (2006) Hereditary breast and ovarian cancer: review and future perspectives. J Mol Med 84(1):16–28PubMedCrossRef
4.
Mohamad HB, Apffelstaedt JP (2008) Counseling for male BRCA mutation carriers: a review. Breast 17(5):441–450PubMedCrossRef
5.
Mitra A, Fisher C, Foster CS et al (2008) Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype. Br J Cancer 98(2):502–507PubMedCrossRef
6.
Mitra AV, Bancroft EK, Barbachano Y et al (2010) Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study. BJU Int 107(1):28–39
7.
Narod SA, Neuhausen S, Vichodez G et al (2008) Rapid progression of prostate cancer in men with a BRCA2 mutation. Br J Cancer 99(2):371–374PubMedCrossRef
8.
Stromsvik N, Raheim M, Oyen N, Gjengedal E (2009) Men in the women’s world of hereditary breast and ovarian cancer–a systematic review. Fam Cancer 8(3):221–229PubMedCrossRef
9.
Hallowell N, Arden-Jones A, Eeles R et al (2006) Guilt, blame and responsibility: men’s understanding of their role in the transmission of BRCA1/2 mutations within their family. Sociol Health Illn 28(7):969–988PubMedCrossRef
10.
Liede A, Metcalfe K, Hanna D et al (2000) Evaluation of the needs of male carriers of mutations in BRCA1 or BRCA2 who have undergone genetic counseling. Am J Hum Genet 67(6):1494–1504PubMedCrossRef
11.
Hallowell N, Ardern-Jones A, Eeles R et al (2005) Men’s decision-making about predictive BRCA1/2 testing: the role of family. J Genet Couns 14(3):207–217PubMedCrossRef
12.
d’Agincourt-Canning L (2001) Experiences of genetic risk: disclosure and the gendering of responsibility. Bioethics 15(3):231–247PubMedCrossRef
13.
Lodder L, Frets PG, Trijsburg RW et al (2001) Men at risk of being a mutation carrier for hereditary breast/ovarian cancer: an exploration of attitudes and psychological functioning during genetic testing. Eur J Hum Genet 9(7):492–500PubMedCrossRef
14.
Hallowell N, Ardern-Jones A, Eeles R et al (2005) Communication about genetic testing in families of male BRCA1/2 carriers and non-carriers: patterns, priorities and problems. Clin Genet 67(6):492–502PubMedCrossRef
15.
McAllister MF, Evans DG, Ormiston W, Daly P (1998) Men in breast cancer families: a preliminary qualitative study of awareness and experience. J Med Genet 35(9):739–744PubMedCrossRef
16.
Daly PA, Nolan C, Green A et al (2003) Predictive testing for BRCA1 and 2 mutations: a male contribution. Ann Oncol 14(4):549–553PubMedCrossRef
17.
Dudok de Wit AC, Tibben A, Frets PG, Meijers-Heijboer EJ, Devilee P, Niermeijer MF (1996) Males at-risk for the BRCA1 gene, the psychological impact. Psychooncology 5:251–257CrossRef
18.
Giorgi A (1985) Phenomeology and psychological research. Duquesne University Press, Pittsburgh
19.
Giorgi A (2009) The descriptive phenomenological method in psychology: a modified Husserlian approach. Duquesne University Press, Pittsburgh
20.
Stromsvik N, Raheim M, Oyen N, Engebretsen LF, Gjengedal E (2010) Stigmatization and male identity: Norwegian males’ experience after identification as BRCA1/2 mutation carriers. J Genet Couns 19(4):360–370PubMedCrossRef
21.
Benner P (1994) Interpretive phenomenology. Sage Publication, California
22.
Chamberlain K, Stephens C, Lyons AC (1997) Encompassing experience: meanings and methods in health psychology. Psychol Health 12:691–709CrossRef
23.
Polkinghorne DE (1995) Narrative configuration in qualitative analysis. In: Hatch JA, Wisniewski R (eds) Life history and narrative. The Falmer Press, London, pp 5–24
24.
Reissman CK (1993) Narrative analysis. Sage Publications, London
25.
Antonovsky A (1987) The mystery of health: how people manage stress and stay well. Jossey bass, San Francisco
26.
27.
Glanz K, Rimer BK, Lewis FM (2002) Health behavior and health education theory, research, and practice. 3rd edn. Jossey-Bass, San Francisco
28.
Finlay E, Stopfer JE, Burlingame E et al (2008) Factors determining dissemination of results and uptake of genetic testing in families with known BRCA1/2 mutations. Genet Test 12(1):81–91PubMedCrossRef
29.
MacDonald DJ, Sarna L, Weitzel JN, Ferrell B (2010) Women’s perceptions of the personal and family impact of genetic cancer risk assessment: focus group findings. J Genet Couns 19(2):148–160PubMedCrossRef
30.
McAllister M, Davies L, Payne K, Nicholls S, Donnai D, MacLeod R (2007) The emotional effects of genetic diseases: implications for clinical genetics. Am J Med Genet A 143A(22):2651–2661PubMedCrossRef
31.
Getz L, Nilsson PM, Hetlevik I (2003) A matter of heart: the general practitioner consultation in an evidence-based world. Scand J Prim Health Care 21(1):3–9PubMedCrossRef
32.
33.
Getz L, Kirkengen AL, Hetlevik I, Romundstad S, Sigurdsson JA (2004) Ethical dilemmas arising from implementation of the European guidelines on cardiovascular disease prevention in clinical practice. A descriptive epidemiological study. Scand J Prim Health Care 22(4):202–208PubMedCrossRef
34.
Stroup AM, Smith KR (2007) Familial effects of BRCA1 genetic mutation testing: changes in perceived family functioning. Cancer Epidemiol Biomarkers Prev 16(1):135–141PubMedCrossRef
35.
Mishler CG (1986) Research interviewing. Context and narrative. Harvard University Press, Cambrigde
Metadata
Title
Cancer worry among Norwegian male BRCA1/2 mutation carriers
Authors
Nina Strømsvik
Målfrid Råheim
Eva Gjengedal
Publication date
01-09-2011
Publisher
Springer Netherlands
Published in
Familial Cancer / Issue 3/2011
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-011-9456-8

Other articles of this Issue 3/2011

Familial Cancer 3/2011 Go to the issue

OriginalPaper

Factors associated with an individuals’ decision to withdraw from genetic counseling for BRCA1 and BRCA2 genes mutations: are personality traits involved?

OriginalPaper

LKB1 signaling in advancing cell differentiation

OriginalPaper

Management of renal tumors in Von Hippel-Lindau disease by percutaneous CT fluoroscopic guided radiofrequency ablation: preliminary results

OriginalPaper

The differential diagnosis of familial lentiginosis syndromes

BriefCommunication

Lack of germline PALB2 mutations in melanoma-prone families with CDKN2A mutations and pancreatic cancer

OriginalPaper

Dendritic cell and macrophage infiltration in microsatellite-unstable and microsatellite-stable colorectal cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits